|
MechanismProtein kinases inhibitors [+2] |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的耐受性及药代动力学研究
[Translation] Study on the tolerability and pharmacokinetics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors
主要目的是考察重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的耐受性,次要目的是评价重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的药代动力学特征。
[Translation] The primary objective was to investigate the tolerability of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors. The secondary objective was to evaluate the pharmacokinetic characteristics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors.
重组人血管内皮抑素注射液联合NP对照安慰剂联合NP治疗初治晚期非小细胞肺癌患者的三期临床研究
[Translation] Phase III clinical study of recombinant human endostatin injection combined with NP versus placebo combined with NP in the treatment of patients with newly diagnosed advanced non-small cell lung cancer
评价重组人血管内皮抑素注射液联合长春瑞滨/顺铂(NP)化疗方案较单纯NP方案在治疗IV期非小细胞肺癌病人(UICC 第7版NSCLC分期定义)的临床生存期获益优势。观察重组人血管内皮抑素注射液联合化疗方案在晚期非小细胞肺癌病人中的安全性。
[Translation] To evaluate the clinical survival benefit of recombinant human endostatin injection combined with vinorelbine/cisplatin (NP) chemotherapy compared with NP alone in the treatment of patients with stage IV non-small cell lung cancer (UICC 7th edition NSCLC staging definition). To observe the safety of recombinant human endostatin injection combined with chemotherapy in patients with advanced non-small cell lung cancer.
100 Clinical Results associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.
0 Patents (Medical) associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.
100 Deals associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.
100 Translational Medicine associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.